August 2005

|
Volume 17 Issue 8
The X-Sizer® (ev3, Inc., Plymouth, Minnesota) is a novel thrombectomy device that effectively removes intracoronary thrombus. Recent studies suggest that pre-treatment with the X-Sizer before percutaneous coronary intervention (PCI) in a thrombus-lad…
Coronary artery perforation is a rare but serious complication of percutaneous coronary intervention (PCI). The incidence is 0.1% with lesions treated by balloon angioplasty and 0.5–3.0% with lesions treated by atheroablative devices.1 It can result…
Several studies have determined the safety and efficacy of percutaneous mitral valvuloplasty (PMV) during pregnancy, the larger series being those recently described by Esteves,122 Nercolini et al.,118 and Ben Farhat et al.120 Retrospectively compari…
Barry George: Needless to say, Fayaz, you have a bias against distal protection, and it’s an emotional issue for those of us who do carotid stenting. Fayaz Shawl: I am not biased, I just think a randomized trial is needed. Barry George: I believe tha…
It is estimated that as many as 20% of Americans ? 65 years old and 50% ? 75 years old have peripheral arterial disease (PAD), a total approaching 14–16 million Americans.1-4 With our rapidly increasing elderly population, it is likely that the incid…
Women with coronary artery disease (CAD) are known to have a higher prevalence of co-morbidities than men, including advanced age, hypertension, diabetes and concomitant non-cardiac disease. Female gender has been shown to be an independent risk fact…
Case Presentation. A 65-year-old gentleman, who works as a professional football referee, presented with progressive symptoms of angina. His job officiating games necessitated significant physical activity and endurance. He presented 10 days prior to…
Dear Readers, This issue of the Journal of Invasive Cardiology contains numerous original clinical research studies and related commentaries. We start the issue with a submission from Dr. Marco Costa and colleagues representing investigators from th…
Treatment options for bypass graft disease, such as repeat CABG and percutaneous revascularization, are limited and provide disappointing outcomes.1-4 Patients undergoing repeat CABG have over a four times greater rate of mortality compared to patien…
Despite the promise of new transcatheter technologies, 400,000 coronary artery bypass (CABG) surgeries are performed each year in the United States, the vast majority incorporating saphenous vein grafts (SVG) as conduits.1 Soon after implantation and…